OUR HR PRACTICE WOULD LIKE TO ANNOUNCE THE PLACEMENT OF
KATE WILSON
AS
HEAD OF TOTAL REWARDS
FOR OUR CLIENT
Moderna is pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. It could transform not only how certain diseases are treated but also how medicines are discovered, developed and manufactured – at a breadth, scale and speed not common in the biopharma industry. Since our founding in 2011, we have built the industry’s leading mRNA technology platform, the infrastructure to accelerate drug discovery and speed early development, a rapidly expanding pipeline, and an unparalleled team. Our development pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials already underway with other development candidates progressing toward the clinic. In addition, we have a number of discovery programs that are advancing toward the development stage.

  For more information on Cooke & White Advisors, please click here !

email: mwhite@cookeandwhite.com  | office:  704.644.1119